Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Vulnerable Plaque Features With Statin Therapy in Diabetic Patients With Coronary Artery Disease: Frequency-Domain Optical Coherence Tomography Analysis

Kohei Takata; Yu Kataoka; Jordan Andrews; Rishi Puri; Muhammad Hammadah; Bhanu Duggal; Samir R. Kapadia; E. Murat Tuzcu; Steven E. Nissen; Stephen J. Nicholls

doi:10.1016/j.jcmg.2018.02.017

Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Vulnerable Plaque Features With Statin Therapy in Diabetic Patients With Coronary Artery Disease: Frequency-Domain Optical Coherence Tomography Analysis

Kohei Takata, Yu Kataoka, Jordan Andrews, Rishi Puri, Muhammad Hammadah, Bhanu Duggal, Samir R. Kapadia, E. Murat Tuzcu, Steven E. Nissen, Stephen J. Nicholls

Producción científica: Letter › revisión exhaustiva

5 Citas (Scopus)

Idioma original	English (US)
Páginas (desde-hasta)	1721-1723
Número de páginas	3
Publicación	JACC: Cardiovascular Imaging
Volumen	11
N.º	11
DOI	https://doi.org/10.1016/j.jcmg.2018.02.017
Estado	Published - nov 2018
Publicado de forma externa	Sí

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Radiology Nuclear Medicine and imaging

Acceder al documento

10.1016/j.jcmg.2018.02.017

Otros archivos y enlaces

Citar esto

Takata, K., Kataoka, Y., Andrews, J., Puri, R., Hammadah, M., Duggal, B., Kapadia, S. R., Tuzcu, E. M., Nissen, S. E., & Nicholls, S. J. (2018). Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Vulnerable Plaque Features With Statin Therapy in Diabetic Patients With Coronary Artery Disease: Frequency-Domain Optical Coherence Tomography Analysis. JACC: Cardiovascular Imaging, 11(11), 1721-1723. https://doi.org/10.1016/j.jcmg.2018.02.017

Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Vulnerable Plaque Features With Statin Therapy in Diabetic Patients With Coronary Artery Disease: Frequency-Domain Optical Coherence Tomography Analysis. / Takata, Kohei; Kataoka, Yu; Andrews, Jordan et al.
En: JACC: Cardiovascular Imaging, Vol. 11, N.º 11, 11.2018, p. 1721-1723.

Producción científica: Letter › revisión exhaustiva

Takata, K, Kataoka, Y, Andrews, J, Puri, R, Hammadah, M, Duggal, B, Kapadia, SR, Tuzcu, EM, Nissen, SE & Nicholls, SJ 2018, 'Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Vulnerable Plaque Features With Statin Therapy in Diabetic Patients With Coronary Artery Disease: Frequency-Domain Optical Coherence Tomography Analysis', JACC: Cardiovascular Imaging, vol. 11, n.º 11, pp. 1721-1723. https://doi.org/10.1016/j.jcmg.2018.02.017

Takata K, Kataoka Y, Andrews J, Puri R, Hammadah M, Duggal B et al. Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Vulnerable Plaque Features With Statin Therapy in Diabetic Patients With Coronary Artery Disease: Frequency-Domain Optical Coherence Tomography Analysis. JACC: Cardiovascular Imaging. 2018 nov;11(11):1721-1723. doi: 10.1016/j.jcmg.2018.02.017

@article{cb60419a6783414688a9205994b5c017,

title = "Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Vulnerable Plaque Features With Statin Therapy in Diabetic Patients With Coronary Artery Disease: Frequency-Domain Optical Coherence Tomography Analysis",

author = "Kohei Takata and Yu Kataoka and Jordan Andrews and Rishi Puri and Muhammad Hammadah and Bhanu Duggal and Kapadia, {Samir R.} and Tuzcu, {E. Murat} and Nissen, {Steven E.} and Nicholls, {Stephen J.}",

note = "Funding Information: Please note: Dr. Nissen has received research support to perform clinical trials through the Cleveland Clinic Coordinating Center for Clinical Research from Pfizer, AstraZeneca, Novartis, Roche, Daiichi-Sankyo, Takeda, Sanofi-Aventis, Resverlogix, and Eli Lilly; and is a consultant or advisor for many pharmaceutical companies but requires them to donate all honoraria or consulting fees directly to charity so that he receives neither income nor a tax deduction. Dr. Nicholls has received speaking honoraria from AstraZeneca, Pfizer, Merck Schering-Plough, and Takeda; has received consulting fees from AstraZeneca, Abbott, Atheronova, Esperion, Amgen, Novartis, Omthera, CSL Behring, Boehringer Ingelheim, Pfizer, Merck Schering-Plough, Takeda, Roche, NovoNordisk, LipoScience, and Anthera; and has received research support from the National Health and Medical Research Council of Australia, Amgen, Esperion, The Medicines Company, Sanofi-Regeneron, Anthera, AstraZeneca, Cerenis, Eli Lilly, InfraReDx, Roche, Resverlogix, Novartis, Amgen, and LipoScience. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. ",

year = "2018",

month = nov,

doi = "10.1016/j.jcmg.2018.02.017",

language = "English (US)",

volume = "11",

pages = "1721--1723",

journal = "JACC: Cardiovascular Imaging",

issn = "1936-878X",

publisher = "Elsevier Inc.",

number = "11",

}

TY - JOUR

T1 - Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Vulnerable Plaque Features With Statin Therapy in Diabetic Patients With Coronary Artery Disease

T2 - Frequency-Domain Optical Coherence Tomography Analysis

AU - Takata, Kohei

AU - Kataoka, Yu

AU - Andrews, Jordan

AU - Puri, Rishi

AU - Hammadah, Muhammad

AU - Duggal, Bhanu

AU - Kapadia, Samir R.

AU - Tuzcu, E. Murat

AU - Nissen, Steven E.

AU - Nicholls, Stephen J.

N1 - Funding Information: Please note: Dr. Nissen has received research support to perform clinical trials through the Cleveland Clinic Coordinating Center for Clinical Research from Pfizer, AstraZeneca, Novartis, Roche, Daiichi-Sankyo, Takeda, Sanofi-Aventis, Resverlogix, and Eli Lilly; and is a consultant or advisor for many pharmaceutical companies but requires them to donate all honoraria or consulting fees directly to charity so that he receives neither income nor a tax deduction. Dr. Nicholls has received speaking honoraria from AstraZeneca, Pfizer, Merck Schering-Plough, and Takeda; has received consulting fees from AstraZeneca, Abbott, Atheronova, Esperion, Amgen, Novartis, Omthera, CSL Behring, Boehringer Ingelheim, Pfizer, Merck Schering-Plough, Takeda, Roche, NovoNordisk, LipoScience, and Anthera; and has received research support from the National Health and Medical Research Council of Australia, Amgen, Esperion, The Medicines Company, Sanofi-Regeneron, Anthera, AstraZeneca, Cerenis, Eli Lilly, InfraReDx, Roche, Resverlogix, Novartis, Amgen, and LipoScience. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2018/11

Y1 - 2018/11

UR - http://www.scopus.com/inward/record.url?scp=85056409406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056409406&partnerID=8YFLogxK

U2 - 10.1016/j.jcmg.2018.02.017

DO - 10.1016/j.jcmg.2018.02.017

M3 - Letter

C2 - 29680344

AN - SCOPUS:85056409406

SN - 1936-878X

VL - 11

SP - 1721

EP - 1723

JO - JACC: Cardiovascular Imaging

JF - JACC: Cardiovascular Imaging

IS - 11

ER -